• Amplia and ANZGOG enter agreement to conduct clinical study in ovarian cancer
• Study to evaluate narmafotinib in combination with standard-of-care chemotherapy
• Focus on safety and exploring potential to improve post-surgical outcomes

Amplia Therapeutics Limited (ASX:ATX; OTCQB:INNMF) and the Australia New Zealand Gynaecological Oncology Group (ANZGOG) have entered into an agreement to conduct a new clinical study investigating Amplia's lead drug narmafotinib in ovarian cancer. Narmafotinib is a best-in-class FAK inhibitor currently undergoing clinical development in pancreatic cancer. The study, led by Dr Gwo Yaw Ho of Monash Health and Monash University, and sponsored and coordinated through ANZGOG, will enrol approximately 15-20 patients with high-grade serous ovarian cancer (HGSOC) who demonstrate poor response to up-front standard-of-care platinum-based chemotherapy prior to planned interval debulking surgery. The trial, called the PRROSE trial, will evaluate the safety of narmafotinib in combination with standard-of-care chemotherapy (carboplatin and paclitaxel) in this patient population. Approximately one in five ovarian cancer patients do not respond adequately to initial chemotherapy, limiting their ability to undergo surgery and contributing to poor clinical outcomes. This study is designed to address this significant unmet medical need and explore whether the addition of narmafotinib can increase the proportion of patients eligible for successful surgical resection. Extensive tissue and blood biomarkers will also be examined to further understand narmafotinib's mechanism of action.

This trial represents an important step in broadening the clinical utility of Amplia's FAK inhibitor program. The study is underpinned by a commitment to translating promising scientific approaches into well-conducted clinical trials that can generate meaningful evidence to inform future treatment options for women with ovarian cancer.